Inside the research
Merit Medical Systems, Inc.
MMSI Research profile · latest available data
Price overview
$87.50
▲ +0.20 (+0.2%)
| 52w hi | $93.18 |
|---|---|
| 52w lo | $60.31 |
| Vol | 354.00K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.37
| Short | +0.25 |
|---|---|
| Medium | +0.48 |
| Long | +0.39 |
computed 2026-09-27
Key fundamentals
Merit Medical Systems, Inc.
Healthcare · Medical Instruments & Supplies
| Market cap | $5.22B |
|---|---|
| Enterprise value | $5.60B |
| Trailing P/E | 36.01x |
| Forward P/E | 18.97x |
| EV / EBITDA | 16.51x |
| P / S (ttm) | 3.31x |
| Profit margin | 9.2% |
| Return on equity | 9.2% |
| Revenue growth | +9.5% |
| Earnings growth | +20.4% |
| Debt / equity | 48.82 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.26 | |
| Sector | +0.08 | |
| Technical | +0.21 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Risk Metrics
| Beta vs SPX | 0.77 |
|---|---|
| Corr SPX | 0.42 |
| Annual vol | 29.2% |
| Annual ret | -2.1% |
| Sharpe | -0.07 |
| Max DD | -45.3% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-30 | Earnings Release, Reg FD Disclosure… | read |
| 2026-05-19 | Officer / Director Change, Bylaws Amendment… | read |
| 2026-04-30 | Earnings Release, Reg FD Disclosure… | read |
| 2026-04-13 | Reg FD Disclosure, Exhibits | read |
| 2026-04-01 | Reg FD Disclosure, Exhibits | read |
| 2026-02-24 | Earnings Release, Reg FD Disclosure… | read |
| 2026-01-08 | Earnings Release, Officer / Director Change… | read |
| 2025-11-13 | Reg FD Disclosure, Exhibits | read |
| 2025-11-03 | Reg FD Disclosure, Exhibits | read |
| 2025-10-30 | Earnings Release, Reg FD Disclosure… | read |
| 2025-10-17 | Reg FD Disclosure, Exhibits | read |
| 2025-10-10 | Officer / Director Change | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Peterson Neil W. | Officer, CHIEF OPERATING | Sell | 21.45K | $1.82M |
| 2026-06-15 | Voigt Michel J. | Officer, CHIEF HUMAN RESO | Gift | 65 | — |
| 2026-06-05 | Lloyd Brian G. | Officer, CHIEF LEGAL OFFI | Gift | 2.00K | — |
| 2026-05-20 | Gunderson Thomas J. | Director | Option exercise | 13.75K | $717.34K |
| 2026-05-20 | Gunderson Thomas J. | Director | Option exercise | 7.50K | $391.27K |
| 2026-05-18 | Ward Lynne N. | Director | Grant | 3.46K | — |
| 2026-05-18 | Ward Scott R. | Director | Grant | 3.46K | — |
| 2026-05-18 | Gunderson Thomas J. | Director | Grant | 3.46K | — |
| 2026-05-18 | Evans Stephen C. | Director | Grant | 3.46K | — |
| 2026-05-18 | Kaiser Laura S. | Director | Grant | 3.46K | — |
Flow & Concentration
| Insider 180d net | -$1.82M |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.52B | +10.8% | |
| Gross profit | $583.87M | +20.6% | |
| Operating income | $184.72M | +20.0% | |
| Net income | $128.49M | +23.3% | |
| Cash from ops | $220.80M | +15.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $87.25 | $87.95 | $86.77 | $87.50 | 354.00K |
| Sep 24 | $87.18 | $87.56 | $86.45 | $87.30 | 743.30K |
| Sep 23 | $86.96 | $88.14 | $86.93 | $87.07 | 611.20K |
| Sep 22 | $86.03 | $87.79 | $85.47 | $87.26 | 682.80K |
| Sep 21 | $85.88 | $86.23 | $84.99 | $85.49 | 379.90K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →